Related Experiment Video

Updated: Apr 26, 2026

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.9K

Multifaceted role of RSPO2: Epigenetics, immunoregulatory, and therapeutic insights in colorectal cancer

Ankit Srivastava1, Nidhi Tyagi1, Mubashra1

  • 1Department of Biotechnology, Motilal Nehru National Institute of Technology, Prayagraj, Allahabad 211004, India.

Biochimica Et Biophysica Acta. Reviews on Cancer
|April 24, 2026
PubMed

Insights

This review explores the role of RSPO2 in colorectal cancer (CRC), integrating epigenetic changes, immune response, and therapeutic strategies. Understanding RSPO2 regulation offers potential for new CRC biomarkers and treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Colorectal cancer (CRC) is marked by epigenetic dysregulation impacting gene expression and tumor growth.
  • Key drivers include APC, TP53, KRAS, CTNNB1, and mismatch repair pathways, with RSPO2 also playing a role.

Purpose of the Study:

  • To provide an integrated perspective on RSPO2 regulation in CRC, linking epigenetics, immune modulation, omics, and therapeutics.
  • To highlight RSPO2 as a potential molecular target for colorectal cancer.

Main Methods:

  • Review of epigenetic modifications and transcriptional regulation of RSPO2.
  • Analysis of immune response, signaling pathways, and therapeutic strategies related to RSPO2.

Main Results:

  • RSPO2 exhibits oncogenic functions in colorectal cancer.
  • Existing research lacks an integrated view of RSPO2's multifaceted role in CRC.

Conclusions:

  • An integrated understanding of RSPO2's epigenetic dynamics and clinical relevance can advance CRC biomarker and therapeutic development.
  • This framework may pave the way for next-generation treatments targeting RSPO2 in colorectal cancer.
Keywords:
CancerColorectal cancerEpigeneticsExpressionImmune responseMethylationRSPO2Therapeutics

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.1K
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

12.3K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.2K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K